LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2022-05-23
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how
well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell
cancer. LET-IMPT is a type of radiation therapy that uses high energy proton "beamlets" to
"paint" the radiation dose into the target and may help to kill tumor cells and shrink
tumors. Giving LET-IMPT and standard chemotherapy may work better in treating patients with
anal canal squamous cell cancer.